Pharmacy Intelligence
GLP-1 impact analysis, specialty drug trends, and generic optimization
GLP-1 medications now represent 20.5% of total pharmacy spend
Year-over-year increase of 67.3% driven by Ozempic, Wegovy, and Mounjaro
18.7%
$1.5M
Total Rx Spend
67.3%
$312K
GLP-1 Spend
24.8%
$487K
Specialty Spend
87.4%
Generic Fill Rate
Pharmacy Spend Trend by Category
12-month rolling analysis
Generic Brand Specialty GLP-1
GLP-1 Drug Breakdown
100 members| Drug | Spend | Members | PMPM | YoY |
|---|---|---|---|---|
| Ozempic (semaglutide) | $124,567 | 34 | $3,665 | +72.4% |
| Wegovy (semaglutide) | $89,234 | 18 | $4,957 | +156.8% |
| Mounjaro (tirzepatide) | $67,890 | 12 | $5,657 | +234.2% |
| Trulicity (dulaglutide) | $23,456 | 28 | $838 | -12.4% |
| Rybelsus (oral sema) | $7,309 | 8 | $914 | +45.7% |
Therapeutic Class Distribution
Antidiabetic Agents
$412KCardiovascular
$287KMental Health
$235KPain Management
$189KRespiratory
$157KOther
$244KAI-Identified Generic Savings
Potential annual savings through generic substitution
$76,080
Lyrica → Pregabalin
23 members
Savings$28,934
Celebrex → Celecoxib
18 members
Savings$19,234
Crestor → Rosuvastatin
45 members
Savings$15,678
Lexapro → Escitalopram
34 members
Savings$12,234